Arovella Therapeutics Ltd has released a press release.
Arovella Therapeutics: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- SANOFI and SUDA Entered Into A Feasibility Agreement
- SUDA Signs Co-Development Deal With Ordesa
- SUDA Appoints Dr Michael Baker CEO
- Case For Share Consolidation and Appendix 3A.3
- SUDA Finalises Agreement With Cann Pharmaceutical
Later from Arovella Therapeutics
- SUDA Signs Additional Licence With Mitsubishi Tanabe
- Anagrelide Cancer Patent For Japan
- Suspension from Official Quotation
- Market Update
- Entitlement Offer To Raise Approximately $3.56 Million
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics